Optimal approach for high-dose methotrexate CNS prophylaxis in DLBCL assessed

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Jun 15 / Springer Healthcare

Optimal approach for high-dose methotrexate CNS prophylaxis in DLBCL assessed

Beatson West of Scotland Cancer Centre, Glasgow, UK

Haematology EHA-2020

Description

Matthew Wilson outlines the key results of their study evaluating the optimal timing for administering high-dose methotrexate to reduce the risk of central nervous system relapse in patients with diffuse large B-cell lymphoma.

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.